The Phase 3 clinical trial, taking place in the USA, will evaluate the efficacy and safety of the candidate vaccine mRNA-1273.
- To demonstrate the efficacy of mRNA-1273 to prevent COVID-19
- To evaluate the safety and reactogenicity of 2 injections of mRNA-1273 given 28 days apart
Type of study: Interventional, clinical trial phase III
Treatment tested: Vaccine
Number of sites: 100
Sample size: 30,000
Study participants: Participants (males and females 18 years of age or older at time of consent), who are at risk of SARS-CoV-2 infection with no known history of SARS-CoV-2 infection
Study status: Recruiting
- Sponsor: Tal Zaks, MD, PhD, Chief Medical Officer ModernaTX, Inc
- Study website
- Study ID: NCT04470427
- Trial registry
Last updated: September 2020
Note that study-related documents posted on the COVID-19 Clinical Research Coalition (COVID-19 CRC) website have been shared by coalition members for information. Some may have been approved by Ethics Review Boards and others may still be in draft form. Documents posted here may have been further amended before being used in the conduct of the respective trials they were designed for. It is recommended that users review these documents carefully and, if they plan to use them, adapt them appropriately for their intended use. The COVID-19 CRC and its members cannot accept any liability for any claim, loss or damages as a result of any reliance placed on, or use of, these documents.